好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Investigation of Maladaptive Health Behavior Engagement and Neurobehavioral and Neurocognitive Outcomes in Former Elite American Football Players
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (11:45 AM-12:45 PM)
9-016

Explore potential associations between football exposure, maladaptive health behaviors, neurobehavioral, and neurocognitive outcomes among former American football players. 

Maladaptive health behavior engagement (e.g., smoking, alcohol use, and substance use) is negatively associated with various neurocognitive and neuropsychiatric outcomes. Chronic traumatic encephalopathy is associated with repetitive head impact exposure. Long-term exposure to playing American football may influence maladaptive health behavior engagement.   
Former professional (n=115) and college-level (n=59) football players and unexposed, asymptomatic controls (n=60) between 45-74 years-old from the DIAGNOSE CTE study were studied. Maladaptive health behaviors included sleep (i.e., MSQ Epworth Sleepiness Scale), cigarette smoking, physical activity, drug, and alcohol use. ANCOVA and regressions (logistic and linear) analyses investigated outcomes within and between subject groups, with respect to neuropsychological assessments based on predetermined cognitive/behavioral factors.

Former football players had more sleep complaints (β = 2.079, p = .007) and alcohol use (β = -1.942, p = .022) than controls, who engaged in less physical activity (odds ratio = .416, p = .041) than former players. No significant differences observed in level of play for health behaviors except opioid use; former college players used more than former NFL players (odds ratio = 3.96, p = .015, padj. = .030). Years of play correlated with Executive Function and Psychomotor Speed factor performance (β = .222, p < .005; padj. = .028). Sleep quality correlated with performances on the Visual Learning and Memory (β = .221, padj.= .038) and Explosivity (β = .406, padj.= .007) factors. Opioid use correlated with performances on the Visual Learning and Memory factor (β = .703, p = .001), Verbal Fluency factor (β = -.212, padj.= .036), the Emotional Dyscontrol factor (β = .227, padj. = .024). 

Sleep problems and opioid use were greater in former American football players and associated with several neuropsychological and neurobehavioral abnormalities. 
Authors/Disclosures
Tahlia Bragg (BU CTE Center)
PRESENTER 		No disclosure on file
Shania Baldwin (BU CTE Center) No disclosure on file
Minna Holleck (Boston University School of Medicine) No disclosure on file
Erika Pettway No disclosure on file
Fatima Tuz-Zahra No disclosure on file
Yorghos Tripodis Yorghos Tripodis has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Medical Association.
Charles Bernick, MD Dr. Bernick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Bernick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Optina. Dr. Bernick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Bernick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corium. Dr. Bernick has stock in Aurora. The institution of Dr. Bernick has received research support from UFC. The institution of Dr. Bernick has received research support from Top Rank Promotions. The institution of Dr. Bernick has received research support from Haymon Boxing.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona) Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine) An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Aaron Ritter, MD (Cleveland Clinic) The institution of Dr. Ritter has received research support from NIH.
Eric M. Reiman, MD (Banner Alzheimer's Institute) Dr. Reiman has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, Green Valley, Zinfandel, and Takeda. Dr. Reiman has received stock or an ownership interest from Alkahest, Alzheon, Aural Analytics, Denali, and United Neuroscience.. Dr. Reiman has received intellectual property interests from a discovery or technology relating to health care. Dr. Reiman has received personal compensation in the range of $500-$4,999 for serving as a Member, National Advisory Council on Aging (NACA) with NIA.
Jeffrey L. Cummings, MD, FAAN Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Martha Shenton Martha Shenton has nothing to disclose.
Robert Stern, PhD (Boston University School of Medicine) Robert Stern, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Robert Stern, PhD has received research support from Eisai. The institution of Robert Stern, PhD has received research support from Lilly. The institution of Robert Stern, PhD has received research support from ATRI/NIA. Robert Stern, PhD has received publishing royalties from a publication relating to health care. Robert Stern, PhD has a non-compensated relationship as a Member with NFLPA Mackey-White Committee that is relevant to AAN interests or activities.
Michael Alosco, PhD (Boston University) The institution of Michael Alosco, PhD has received research support from NIH. The institution of Michael Alosco, PhD has received research support from Life Molecular Imaging Inc.
Robert Turner No disclosure on file